ABOUT THIS EPISODE
Brain cancers are notoriously difficult to manage with current treatments offering limited effectiveness. But what if there was a way to change that? Michael Roberts from Adaptin Bio joins Owen Bryant to explore how a pioneering new treatment called BRiTE is driving hope for improved outcomes for patients.
English
United Kingdom
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of P4A Let's Talk Rare: The Life Science Podcast.
OTHER EPISODES IN THIS PODCAST
After3 years in the making, the Joint Clinical Assessment for the EU is in effect.
From 12th January 2025 new cancer medicines and advanced therapy medicinal products (ATMPs) will require a JCA across all 27 member states.
Join Owen and Georgie, along with guests Darren Callanan and Sam Morris…
Dive into P4A's annual appraisal of the year ahead. In this episode of Let's Talk Rare we examine the most important trends as identified and voted for by the P4A team.
Ranging from Donald Trump's tariff impact on EU's ability to price orphan drugs to the change of mindset in HTA bodies to inclu…
In the latest episode of Let's Talk Rare, Owen Bryant & Georgie Rack delve into the world of drug development in rare diseases.
They are joined by the brilliant Rob Freishtat, president of Uncommon Cures. Rob brings unique insights on who the key stakeholder are in developing drugs and the man…
Discover how artificial intelligence is transforming the future of rare disease research in the latest episode of Let’s Talk Rare, the official podcast from Partners4Access (P4A).
Join us as we sit down with Ilya Burkov, AI expert at Nebius to explore how cutting-edge machine learning tools are ac…
Disclaimer: The podcast and artwork embedded on this page are from Partners4Access, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
